Imiphumela emibi ye-cardiovascular ihluke phakathi kweCelebrex, i-Vioxx, ne-NSAID endala.
Lesi sihloko siyingxenye ye- Arthritis Archives.
Inothi lomhleli: Ngomhlaka 09/30/2004, uMerck umenzi we-Vioxx, wakhipha ukukhumbula emhlabeni wonke, wanqanda ukuthengisa kwalesi sidakamizwa. Ngomhla ka-04/07/2005, ngemuva kokuhlolisisa iklasi lezidakamizwa ze-arthritis ezaziwa njenge-NSAID kanye ne-COX-2 inhibitors, i-FDA yamemezela izenzo ezihleliwe zokulawula.
Idatha: May 29, 2004
Ucwaningo lwaseCanada lubonisa ukuthi i-Celebrex ingaba yi-Anti-Inflammatory Drug kubantu abadala
Abantu abanezimpawu ze-arthritis bavame ukushiwo esinye sezidakamizwa ezingezona okhethwayo, okungezona ezakhelwe ukuvuvukala (ama-NSAID) noma enye yeqembu elisha le-NSAIDS eyaziwa njenge-cyclo-oxygenase-2 inhibitors ( COX-2 inhibitors ekhethiwe ).
Ama-NSAID angakhethi ahlotshaniswa nengozi eyengeziwe yokwehluleka kwenhliziyo. Okuncane okungaziwa noma sekuphethwe ngemiphumela ye-cardiovascular of COX-2 inhibitors ekhethiwe.
I-Lancet (2004; 363: 1751-56) yembula imiphumela yocwaningo lwaseCanada olubandakanya abantu abangaphezu kuka-130 000 asebekhulile. U-Muhammad Mamdani wase-Institute for Clinical Evaluative Sciences, eToronto, eCanada, kanye nozakwethu wenza ukuhlaziywa okubukeka kokungena kokungenwa kwesibhedlela ngokuhluleka kwenhliziyo nxazonke:
- Abantu abangu-14 500 basebenzisa i-COX-2 inhibitor Vioxx (rofecoxib)
- Abantu abayi-19,000 basebenzisa i-COX-2 inhibitor Celebrex (celecoxib)
- Abantu abangu-5 400 basebenzisa ama-NSAID angakhethi
- Abantu abayi-100,000 abangasebenzisi noma iyiphi i-NSAID ekhonza njengeqembu lokulawula
Imiphumela Yokufundwa
Uma kuqhathaniswa neqembu lokulawula labasebenzisi abangewona i-NSAID, imiphumela yilezi:
- Abantu abasebenzisa i-Vioxx babenengozi engama-80% yokwamukelwa esibhedlela ngenxa yokuhluleka kwenhliziyo.
- Abantu abasebenzisa ama-NSAID angewona okhethekile banomngcipheko we-40% wokungenwa kwe-heart congestive failure.
- Abantu abasebenzisa i-Celebrex banesilinganiso esifanayo sokwamukela esibhedlela ngenxa yokuhluleka kwenhliziyo njengabantu abangakaze basebenzise ama-NSAID.
Ukungezwani phakathi kwe-NSAIDS okungewona okhethiwe kanye ne-COX-2 inhibitors ngamunye ekuvunyelwene ngayo ukungenwa kwe-heart congestive failure kungase kubonise isidingo sokuhlolwa okulinganiselwe, okungahleliwe, okulawulwa ukuze kuqhutshekwe ukutadisha okuqhubekayo.
Izinsiza ezihlobene
- I-Celebrex (i-Celecoxib)
- I- Vioxx (i-Rofecoxib)
- I-COX-2 Inhibitors Ekhethiwe
- Okuningi mayelana NSAIDs
- Imithi ye-Arthritis
Umthombo: I-COX-2 Inhibitor ingaba yi-Safest Anti-Inflammatory Drug kubantu abadala, i-Lancet Issue 29 Meyi 2004
Ishicilelwe okokuqala: 05/29/2004